| Brickell Biotech is engaged in the research and development of biopharmaceutical products, including those based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Co. was focused on developing its novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis. VL-2397 was being evaluated in a multicenter, open label randomized Phase 2 clinical study, designed to compare the efficacy and safety of VL-2397 to standard treatment for invasive aspergillosis in acute leukemia patients and recipients of allogeneic hematopoietic cell transplant. We show 14 historical shares outstanding datapoints in our VICL shares outstanding history coverage, used to compute VICL market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VICL market cap history over the course of time is important for investors
interested in comparing VICL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VICL versus a peer is one thing; comparing
VICL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VICL can fluctuate over the course of history.
With this page we aim to empower investors researching VICL by allowing them to research the VICL market cap history.